ThomasP.LeistMDPhD

PubMed

• A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study.
  Gavin Giovannoni, Alexey Boyko, Jorge Correale, Gilles Edan, Mark S Freedman, Xavier Montalban, Kottil Rammohan, Dusan Stefoski, Bassem Yamout, Thomas Leist, Aida Ayde...> ;Neurodegenerative Disease Management. 2023 Oct 1
• A retrospective claims analysis of fatigue in patients with multiple sclerosis on disease-modifying therapy.
  Thomas P Leist, Michele Cole, Alex Keenan, Hoa H Le, Verma, S.> ;Multiple Sclerosis and Related Disorders. 2023 Oct 1
• 2 citations
  Revealing the immune cell subtype reconstitution profile in patients from the CLARITY study using deconvolution algorithms after cladribine tablets treatment.
  Irina Kalatskaya, Gavin Giovannoni, Thomas Leist, Joseph Cerra, Ursula Boschert, P Alexander Rolfe> ;Scientific Reports. 2023 May 18
• 6 citations
  Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study.
  Gavin Giovannoni, Alexey Boyko, Jorge Correale, Gilles Edan, Mark S Freedman, Xavier Montalban, Kottil Rammohan, Dusan Stefoski, Bassem Yamout, Thomas Leist, Aida Ayde...> ;Multiple Sclerosis. 2023 May 1
• 5 citations
  T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy.
  Anthony T Reder, Olaf Stuve, Stephanie K Tankou, Thomas P Leist> ;Multiple Sclerosis. 2023 May 1
• Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary.
  Nicola De Stefano, Maria Pia Sormani, Gavin Giovannoni, Kottil Rammohan, Thomas P Leist, Patricia K Coyle, Fernando Dangond, Nektaria Alexandri, Andrew Galazka> ;Neurodegenerative Disease Management. 2022 Dec 1
• 2 citations
  Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summary.
  Jiwon Oh, Bryan Walker, Gavin Giovannoni, Dominic Jack, Fernando Dangond, Axel Nolting, Julie Aldridge, Lori A Lebson, Thomas P Leist> ;Neurodegenerative Disease Management. 2022 Feb 1
• 1 citations
  Multiple sclerosis: relationship between locus of control and quality of life in persons with low versus high disability.
  Judith Bijoux Leist, Thomas P Leist> ;Health Psychology and Behavioral Medicine. 2022 Jan 1
• 14 citations
  Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial.
  Bianca Weinstock-Guttman, Robert A. Bermel, Gary Cutter, Mark S. Freedman, Thomas Leist, Xiaoye Ma, Deidre Kile, B Musch, Anthony T. Reder, Jerry S. Wolinsky> ;Multiple Sclerosis. 2021 Aug 12
• 5 citations
  Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis:
  Jiwon Oh, Bryan Walker, Gavin Giovannoni, Dominic Jack, Fernando Dangond, Axel Nolting, Julie Aldridge, Lori A Lebson, Thomas Leist> ;Multiple Sclerosis Journal - Experimental, Translational and Clinical. 2021 Jul 13
• 4 citations
  N-acetyl cysteine administration affects cerebral blood flow as measured by arterial spin labeling MRI in patients with multiple sclerosis
  Shiva Shahrampour, Justin Heholt, Andrew Wang, Faezeh Vedaei, Feroze B. Mohamed, Mahdi Alizadeh, Ze Wang, George Zabrecky, Nancy Wintering, Anthony J. Bazzan, Thomas L...> ;Heliyon. 2021 Jul 1
• 14 citations
  Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
  Nicola De Stefano, Maria Pia Sormani, Gavin Giovannoni, Kottil Rammohan, Thomas Leist, Patricia K. Coyle, Fernando Dangond, B. Keller, Nektaria Alexandri, Andrew Galazka> ;Multiple Sclerosis. 2021 May 10
• 4 citations
  Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study.
  Bruce A.C. Cree, James D. Bowen, Hans-Peter Hartung, Patrick Vermersch, Bruce Hughes, Doris Damian, Yann Hyvert, Fernando Dangond, Andrew Galazka, Megan Grosso, Daniel...> ;Multiple Sclerosis and Related Disorders. 2021 Apr 1
• 3 citations
  Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study.
  Mark S. Freedman, Patricia K. Coyle, Giancarlo Comi, Susan Scarberry, Doris Damian, Yann Hyvert, Fernando Dangond, Andrew Galazka, Dominic Jack, Lori A Lebson, Thomas ...> ;Multiple Sclerosis Journal - Experimental, Translational and Clinical. 2021 Feb 24
• 17 citations
  Challenges in multiple sclerosis care: Results from an international mixed-methods study.
  Sophie Péloquin, Klaus Schmierer, Thomas Leist, Jiwon Oh, Suzanne Murray, Patrice Lazure> ;Multiple Sclerosis and Related Disorders. 2021 Feb 23
• Physician Compensation in the United States – Through the Lens of the MS Neurologist
  Joseph R. Berger, Thomas Leist, Benjamin Greenberg, Kottil Rammohan> ;Multiple Sclerosis and Related Disorders. 2021 Feb 17
• 3 citations
  Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets.
  Gavin Giovannoni, Patricia K Coyle, Patrick Vermersch, Bryan Walker, Julie Aldridge, Axel Nolting, Andrew Galazka, Caroline Lemieux, Thomas P Leist> ;Frontiers in Immunology. 2021 Jan 1
• 49 citations
  Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.
  Bruce A.C. Cree, Gary Cutter, Jerry S. Wolinsky, M. S. Freedman, Giancarlo Comi, Gavin Giovannoni, Hans-Peter Hartung, Douglas L. Arnold, Jens Kuhle, Valerie J Block, ...> ;The Lancet. Neurology. 2020 Dec 1
• 34 citations
  The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review
  Kottil Rammohan, Patricia K. Coyle, Elke Sylvester, Andrew Galazka, Fernando Dangond, Megan Grosso, Thomas Leist> ;Drugs. 2020 Dec 1
• 31 citations
  Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis.
  Thomas Leist, Stuart D. Cook, G. Comi, Xavier Montalban, Gavin Giovannoni, Axel Nolting, Doris Damian, Sana Syed, Andrew Galazka> ;Multiple Sclerosis and Related Disorders. 2020 Oct 8
• 16 citations
  Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety.
  Gavin Giovannoni, Andrew Galazka, Regina Schick, Thomas Leist, Giancarlo Comi, Xavier Montalban, Doris Damian, Fernando Dangond, Stuart D. Cook> ;Drug Safety. 2020 Jul 1
• 16 citations
  N-acetyl Cysteine Administration Is Associated With Increased Cerebral Glucose Metabolism in Patients With Multiple Sclerosis: An Exploratory Study
  Daniela Monti, George Zabrecky, Thomas Leist, Nancy Wintering, Anthony J. Bazzan, Tingting Zhan, Andrew B. Newberg> ;Frontiers in Neurology. 2020 Feb 14
• 4 citations
  The Relationship Between Multiple Sclerosis Symptom Severity Measures and Performance on Driving Variability Metrics in a Virtual Reality Simulator.
  Ann-Marie A Raphail, Kayci L Vickers, Thomas Leist, Maria T. Schultheis> ;American Journal of Physical Medicine & Rehabilitation. 2020 Apr 1
• 76 citations
  Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers:
  Olaf Stüve, Per Soelberg Soerensen, Thomas Leist, Gavin Giovannoni, Yann Hyvert, Doris Damian, Fernando Dangond, Ursula Boschert> ;Therapeutic Advances in Neurological Disorders. 2019 Jun 18
• 81 citations
  Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis
  Stuart D. Cook, Thomas Leist, Giancarlo Comi, Xavier Montalban, Gavin Giovannoni, Axel Nolting, Christine Hicking, Andrew Galazka, Elke Sylvester> ;Multiple Sclerosis and Related Disorders. 2019 Apr 1
• Join now to see all